Dr. Garren thinks thinks that 534 will find uses in solid tumors as well. He is expecting results on those studies later next year, so the market for the drug, if he's right (and he's an oncologist), could go well beyond the hematological indications.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.